(Q37242676)

19 August 2017

1 reference

title

Epothilones in breast cancer: current status and future directions (English)

1 reference

19 August 2017

Francesco Atzori

1

1 reference

19 August 2017

Monica Fornier

series ordinal

2

1 reference

19 August 2017

publication date

1 August 2008

1 reference

Expert Review of Anticancer Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

8

1 reference

19 August 2017

issue

8

1 reference

19 August 2017

page(s)

1299-1311

1 reference

Relationships between the structure of taxol analogs and their antimitotic activity

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Targeting multidrug resistance in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Molecular dissection of the microtubule depolymerizing activity of mitotic centromere-associated kinesin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Differential binding regulation of microtubule-associated proteins MAP1A, MAP1B, and MAP2 by tubulin polyglutamylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Description of a short-term Taxol-induced nociceptive neuropathy in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

The clinical development of new mitotic inhibitors that stabilize the microtubule

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Repeat motifs of tau bind to the insides of microtubules in the absence of taxol

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

The binding mode of epothilone A on alpha,beta-tubulin by electron crystallography

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Synthesis of epothilones A and B in solid and solution phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

In vivo metabolism of epothilone B in tumor-bearing nude mice: identification of three new epothilone B metabolites by capillary high-pressure liquid chromatography/mass spectrometry/tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Markers predicting clinical benefit in breast cancer from microtubule-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

A Phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.8.8.1299

Epothilone A and B—Novel 16-Membered Macrolides with Cytotoxic Activity: Isolation, Crystal Structure, and Conformation in Solution

21 January 2018

1 reference

9 March 2024

https://opencitations.net/index/api/v1/citations/10.1002/ANIE.199615671

Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.49.560

Identifiers

DOI

10.1586/14737140.8.8.1299

1 reference

19 August 2017

1 reference